Format

Send to

Choose Destination
Biochim Biophys Acta Gene Regul Mech. 2017 Nov;1860(11):1117-1126. doi: 10.1016/j.bbagrm.2017.08.007. Epub 2017 Sep 7.

Altered expression of the FMR1 splicing variants landscape in premutation carriers.

Author information

1
Pacific Biosciences, Inc., Menlo Park, CA 94025, USA.
2
Biochemistry and Molecular Medicine, UC Davis, Sacramento, CA 95817, USA.
3
Biochemistry and Molecular Medicine, UC Davis, Sacramento, CA 95817, USA; MIND Institute, UC Davis, Sacramento, CA 95817, USA. Electronic address: ftassone@ucdavis.edu.

Abstract

FMR1 premutation carriers (55-200 CGG repeats) are at risk for developing Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), an adult onset neurodegenerative disorder. Approximately 20% of female carriers will develop Fragile X-associated Primary Ovarian Insufficiency (FXPOI), in addition to a number of clinical problems affecting premutation carriers throughout their life span. Marked elevation in FMR1 mRNA levels have been observed with premutation alleles resulting in RNA toxicity, the leading molecular mechanism proposed for the FMR1 associated disorders observed in premutation carriers. The FMR1 gene undergoes alternative splicing and we have recently reported that the relative abundance of all FMR1 mRNA isoforms is significantly increased in premutation carriers. In this study, we characterized the transcriptional FMR1 isoforms distribution pattern in different tissues and identified a total of 49 isoforms, some of which observed only in premutation carriers and which might play a role in the pathogenesis of FXTAS. Further, we investigated the distribution pattern and expression levels of the FMR1 isoforms in asymptomatic premutation carriers and in those with FXTAS and found no significant differences between the two groups. Our findings suggest that the characterization of the expression levels of the different FMR1 isoforms is fundamental for understanding the regulation of the FMR1 gene as imbalance in their expression could lead to an altered functional diversity with neurotoxic consequences. Their characterization will also help to elucidating the mechanism(s) by which "toxic gain of function" of the FMR1 mRNA may play a role in FXTAS and/or in the other FMR1-associated conditions.

KEYWORDS:

Alternative splicing; FMR1 gene; FXTAS; Isoforms; RNA toxicity; SMRT sequencing

PMID:
28888471
PMCID:
PMC5933929
DOI:
10.1016/j.bbagrm.2017.08.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center